ProCE Banner Activity

Einblicke in neue Daten zu BTK-Inhibitoren bei CLL und MCL der Jahresversammlung der SOHO 2022

Clinical Thought
In dieser Stellungnahme diskutieren 2 Experten die Auswirkungen der auf der Jahresversammlung der SOHO 2022 vorgestellten Daten aus klinischen Studien zu BTK-Inhibitor-basierten Behandlungen für Patienten mit chronischer lymphatischer Leukämie und Mantelzell-Lymphom.

Released: November 28, 2022

Share

Faculty

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Director, Lymphoma Program
Medical Director, Oncology Data Center
Assistant Professor
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Emory University
Atlanta, Georgia

Kami Maddocks

Kami Maddocks, MD

Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Christopher R. Flowers, MD, MS

Director, Lymphoma Program
Medical Director, Oncology Data Center
Assistant Professor
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Emory University
Atlanta, Georgia

Christopher R. Flowers, MD, MS: consulting/advisory/speaker: AstraZeneca, Bayer, BeiGene, BioAscend, Bristol-Myers Squibb, Celgene, Curio Sciences, Denovo Biopharma, Epizyme/Incyte, Foresight Diagnostics, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys, N-Power, Pharmacyclics/Janssen, SeaGen; stock options: Foresight Diagnostics, N-Power; research funding (institution): 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceuticals, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm.

Kami Maddocks, MD

Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio

Kami Maddocks, MD: consultant/advisor/speaker: AbbVie, Acerta, ADC Therapeutics, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Genmab, Gilead, Incyte, Janssen, Kite, Lilly, MorphoSys, Pharmacyclics.